Ipsos Asthma Study Expands in Asia

Ipsos is extending its syndicated Severe Asthma Therapy Monitor to Japan, the first country covered in Asia; and says it will add China later this year.

Already running in the US, UK, France, Germany, Spain, Italy and the Netherlands, the study provides a 360 degree perspective on the dynamic severe asthma treatment landscape, and the launch will give data on the changing market shares of relevant treatments in Japan as well as key reasons behind treatment decisions and how patients move through the treatment pathway. Using Ipsos' proprietary future market mapping methodology RxPECT, subscribers can identify the types of patient for which physicians would consider prescribing novel therapies, which attributes will drive those treatment decisions, and the performance of specific products.

Eric Perrot, who will manage the new service, comments: 'The number of asthma patients in Japan has continued to increase since 2008. Inhaled corticosteroids have historically been the main treatment for asthma, but some severe manifestations of asthma remained difficult to control and treat. The introduction of the first biologic therapy in 2012, followed by others in subsequent years, offered new options of treatment for severe asthma. The recent approval in March 2019 of the fourth targeted biologic drug has further increased competition among biologics. These many developments heighten the need for real-world evidence to provide an ongoing understanding of market trends, competition activities and market potential'.

Ipsos' Healthcare Service Line operates in more than fifty and employs more than 1,000 people. The group is online at www.ipsos.com .